Los Angeles Capital Management LLC increased its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) by 8.9% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 65,322 shares of the company's stock after purchasing an additional 5,352 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.09% of Kiniksa Pharmaceuticals worth $649,000 as of its most recent filing with the SEC.
Several other large investors have also recently made changes to their positions in the company. Rice Hall James & Associates LLC increased its position in shares of Kiniksa Pharmaceuticals by 13.9% during the first quarter. Rice Hall James & Associates LLC now owns 811,922 shares of the company's stock worth $8,071,000 after purchasing an additional 99,115 shares in the last quarter. New York State Common Retirement Fund grew its holdings in Kiniksa Pharmaceuticals by 25.7% in the 1st quarter. New York State Common Retirement Fund now owns 43,094 shares of the company's stock valued at $428,000 after buying an additional 8,817 shares in the last quarter. Waldron Private Wealth LLC purchased a new stake in Kiniksa Pharmaceuticals in the 1st quarter valued at $374,000. Jackson Creek Investment Advisors LLC grew its holdings in Kiniksa Pharmaceuticals by 6.4% in the 1st quarter. Jackson Creek Investment Advisors LLC now owns 81,995 shares of the company's stock valued at $815,000 after buying an additional 4,926 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in Kiniksa Pharmaceuticals by 2.1% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 71,384 shares of the company's stock valued at $710,000 after buying an additional 1,457 shares in the last quarter. 42.57% of the stock is currently owned by hedge funds and other institutional investors.
Get
Kiniksa Pharmaceuticals alerts:
Kiniksa Pharmaceuticals Stock Up 2.1 %
Shares of NASDAQ:KNSA opened at $12.41 on Friday. The business has a fifty day moving average of $10.44 and a two-hundred day moving average of $10.09. The stock has a market cap of $862.12 million, a P/E ratio of -7.66 and a beta of -0.12. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $7.36 and a 52-week high of $15.24.
About Kiniksa Pharmaceuticals
(Get Rating)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Further Reading
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- MarketBeat: Week in Review 8/8 – 8/12
- 2 Important Retail Stock Battles to Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating).
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
